Observational studyThe Journal of infectious diseases2019
Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study.
Observational study in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The number of cases, mortality and treatments of viral hemorrhagic fevers: A systematic review.PLoS neglected tropical diseases · 2022Pooled it
- Identification of Host Gene Transcripts by Machine Learning and Their Application to Predict Outcome in Ebola Virus Disease.The Journal of infectious diseases · 2026Article
- Article
- Article
- Pharmacogenomic Studies of Antiviral Drug Favipiravir.Pharmaceutics · 2024Article
- Derivation and Internal Validation of a Mortality Prognostication Machine Learning Model in Ebola Virus Disease Based on Iterative Point-of-Care Biomarkers.Open forum infectious diseases · 2024Article
- Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022.Orphanet journal of rare diseases · 2023Article
- Extracts ofPharmaceutical biology · 2023Article
- Review
- Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir.Diagnostic microbiology and infectious disease · 2022Article
- Therapeutic Strategies against Ebola Virus Infection.Viruses · 2022Review
- Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Favipiravir treatment prolongs the survival in a lethal mouse model intracerebrally inoculated with Jamestown Canyon virus.PLoS neglected tropical diseases · 2021Article
- Development and Validation of a Method for Quantification of Favipiravir as COVID-19 Management in Spiked Human Plasma.Molecules (Basel, Switzerland) · 2021Article
- Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates.PLoS neglected tropical diseases · 2021Article
- A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.Viruses · 2020Article
- Current treatment of COVID-19 in renal patients: hope or hype?Internal and emergency medicine · 2020Review
- Evaluating case definitions for Ebola virus disease.The Lancet. Infectious diseases · 2020Article
- Favipiravir: A new and emerging antiviral option in COVID-19.Medical journal, Armed Forces India · 2020Review
- Marburg virus disease: A summary for clinicians.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
73 authors.
Funding
Abstract
backgroundIn 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients. The cycle threshold (Ct) of an Ebola virus-specific reverse transcription-polymerase chain reaction assay and 13 blood chemistry parameters were measured on admission and during hospitalization. Favipiravir treatment was offered to patients with EVD on a compassionate-use basis.
methodsTo reduce biases in the raw field data, we carefully selected 163 of 286 patients with EVD for a retrospective study to assess associations between potential risk factors, alterations in blood chemistry findings, favipiravir treatment, and outcome.
resultsThe case-fatality rate in favipiravir-treated patients was lower than in untreated patients (42.5% [31 of 73] vs 57.8% [52 of 90]; P = .053 by univariate analysis). In multivariate regression analysis, a higher Ct and a younger age were associated with survival (P < .001), while favipiravir treatment showed no statistically significant effect (P = .11). However, Kaplan-Meier analysis indicated a longer survival time in the favipiravir-treated group (P = .015). The study also showed characteristic changes in blood chemistry findings in patients who died, compared with survivors.
conclusionsConsistent with the JIKI trial, this retrospective study revealed a trend toward improved survival in favipiravir- treated patients; however, the effect of treatment was not statistically significant, except for its influence on survival time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.